In April 2026, COMPASS Pathways announced that the FDA granted a rolling NDA review for its synthetic psilocybin therapy COMP360 in treatment-resistant depression and selected it for the ...

风险批露: 交易股票、外汇、商品、期货、债券、基金等金融工具或加密货币属高风险行为，这些风险包括损失您的部分或全部投资金额，所以交易并非适合所有投资者。加密货币价格极易波动，可能受金融、监管或政治事件等外部因素的影响。保证金交易会放大金融风险。 在决定交易任何金融工具或加密货币前，您应当充分了解与金融市场交易相关的风险和成本，并谨慎考虑您的投资目标、经验水平以及风险偏好，必要时应当寻求专业意见。

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial ...

LONDON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Fintel reports that on May 4, 2026, Jefferies initiated coverage of COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) ...

Compass Pathways may be the first to benefit from an accelerated approval process.

Compass Pathways PLC CMPS said a White House executive order aimed at accelerating mental health treatment research could help speed access to its experimental psilocybin therapy, which the company ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the ...

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance ...

Why COMPASS Pathways is Back on Investors’ Radar Interest in COMPASS Pathways (NasdaqGS:CMPS) has picked up after a White ...